CLL Society Education On Demand: Is There Good News Ahead? Update on Omicron and Beyond / Available Therapies for COVID-19
Recorded Friday, March 18, 2022
Description:
As we enter our third year of the COVID-19 pandemic with the rise of the Omicron variant and promising news from the scientific community about more therapeutic options for those who are infected with COVID-19 and options for pre-exposure prophylaxis, we remain hopeful for the future.
Join infectious disease specialist Dr. Joshua Hill and CLL expert Dr. Sameer Parikh who will give brief updates about where we are today and then spend the majority of the event answering your questions. It is critical that CLL patients and caregivers continue to receive up-to-date and credible information from a spectrum of expert voices.
Welcome
Robyn Brumble, MSN, RN
Director of Scientific Affairs and Research
CLL Society
Moderator
Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd
Executive Vice President and Chief Medical Officer
CLL Society
Speaker
Joshua A. Hill, MD
Assistant Professor
Vaccine and Infectious Disease Division and Clinical Research Division
Fred Hutch
Speaker
Sameer Parikh, MD, MBBS
Assistant Professor of Medicine, Hematology
Consultant, Division of Hematology
Mayo Clinic
CLL Society Resources
- Download Slides
- Audience Questions & Answers
- COVID-19 Webpage
- COVID-19 Plan: Checklists for Chronic Lymphocytic Leukemia (CLL) Preparing for Pre and Post COVID-19 Exposure
- Monoclonal Antibodies for CLL and Other High-Risk Patients Who Test Positive for COVID-19
- Explaining to Family and Friends Why the General CDC Guidelines for Those Vaccinated Against COVID-19 Do Not Apply to Chronic Lymphocytic Leukemia Patients
- CLL Society’s Official COVID-19 Triage Statement
- CLL Patients and Protection against COVID-19: Passive and Active Immunity
- CDC Recommendations for Fully Vaccinated People and What it Means for CLL Patients
- Sign up for CLL Society Weekly Emails
- CLL Society Support Groups
This program was made possible by grant support from Regeneron, Pharmacyclics, and Janssen.
